In Response to the Letter to the Editor by Romach Et al. Re Our Publication "Dolutegravir in Pregnant Mice is Associated with Increased Rates of Fetal Defects at Therapeutic but Not at Supratherapeutic Levels"
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Posobiec L, Chapman S, Murzyn S, Rendemonti J, Stanislaus D, Romach E
. No developmental toxicity observed with dolutegravir in rat whole embryo culture. Birth Defects Res. 2021; 113(16):1190-1197.
DOI: 10.1002/bdr2.1949.
View
2.
Mohan H, Lenis M, Laurette E, Tejada O, Sanghvi T, Leung K
. Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels. EBioMedicine. 2020; 63:103167.
PMC: 7753150.
DOI: 10.1016/j.ebiom.2020.103167.
View
3.
Zash R, Holmes L, Diseko M, Jacobson D, Brummel S, Mayondi G
. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019; 381(9):827-840.
PMC: 6995896.
DOI: 10.1056/NEJMoa1905230.
View
4.
Cabrera R, Souder J, Steele J, Yeo L, Tukeman G, Gorelick D
. The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid. AIDS. 2019; 33(13):1967-1976.
PMC: 6774845.
DOI: 10.1097/QAD.0000000000002289.
View
5.
Stanislaus D, Posobiec L, Laffan S, Solomon H, Ziejewski M, Romach E
. Absence of developmental and reproductive toxicity in animals exposed to dolutegravir. Birth Defects Res. 2019; 112(3):245-261.
DOI: 10.1002/bdr2.1635.
View